Business
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney
About this update from Fresenius Medical Care Ag
[{"type":"text","content":"Press Release\n Shareholders approve proposed dividend of EUR 1.49 per share\n \n \n FME Reignite strategy launched in 2025 successfully drives the next phase of value creation\n \n \n 5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026\n \n \n EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programs\n \n Bad Homburg (May 21, 2026) - Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three years, the Company has successfully delivered on its mid term financial and strategic targets set for 2025. Building on this transformation, Fresenius Medical Care is now focused on executing its FME Reignite strategy and advancing sustainable value creation.\n \n \n \n At today's Annual General Meeting, Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, said, \"We are firmly operating in a new time, defined by geopolitical uncertainty, transactional global relationships, and market volatility. For a global healthcare company such as Fresenius Medical Care, adaptability is decisive. The ability to recognize changes early on and anticipate them will be essential for success. For this, the Company laid the groundwork last year.\"\n \n \n Michael Sen added, \"Fresenius Medical Care looks back on a strong year. Financial performance and margins have improved, and leverage has been reduced. Organic revenue growth reached 8 percent1, driven by positive contributions from all operating segments. On behalf of the Supervisory Board, I thank the Management Board, under the leadership of Helen Giza, and all 110,000 employees of Fresenius Medical Care for their performance. More than 44 million dialysis treatments delivered worldwide, and life-sustaining medical technology supplied to patients in 140 countries are impressive figures. The Company did a lot of things right last year and is now well-positioned. I am confident that Fresenius Medical Care will continue to provide top-tier kidney care in the future while also achieving financial success.\"\n Helen Giza, CEO and Chair of the Management Board o...